Platelet-Rich Fibrin: Biological Properties and Clinical Applications

Introduction

Platelet-rich fibrin (PRF), a second-generation platelet concentrate, has emerged as one of the most widely adopted autologous biomaterials in contemporary dentistry and oral surgery. Developed by Dr. Joseph Choukroun and colleagues in France in 2001, PRF represents a conceptual evolution from first-generation platelet concentrates, including platelet-rich plasma (PRP), by eliminating the need for anticoagulants and exogenous thrombin or calcium chloride activators. The simplicity of PRF preparation—requiring only a venous blood sample, a centrifuge, and a sterile field—combined with its favorable biological properties and autologous nature has driven its rapid adoption across implantology, periodontics, oral surgery, and regenerative endodontics.

PRF is distinguished from PRP by its unique three-dimensional fibrin matrix architecture, which serves as a scaffold for cellular migration and proliferation while simultaneously providing a sustained-release reservoir for growth factors and cytokines. The absence of anticoagulants in PRF preparation allows the physiological polymerization of fibrinogen into a dense, cross-linked fibrin network that mimics the natural blood clot structure. This biomimetic architecture supports the coordinated processes of hemostasis, inflammation, proliferation, and remodeling that characterize wound healing.

This article provides a comprehensive review of platelet-rich fibrin, examining the biological principles underlying its regenerative potential, detailing preparation protocols and their influence on PRF composition, evaluating the evidence base for its diverse clinical applications, and discussing future directions in PRF research and development. By synthesizing the extensive preclinical and clinical literature, the article aims to provide clinicians with an evidence-based framework for incorporating PRF into their surgical practice.

Classification and Types of Platelet Concentrates

Platelet concentrates used in dentistry and medicine have evolved through several generations, each distinguished by preparation protocol, cellular composition, and fibrin architecture. Understanding this classification is essential for interpreting the heterogeneous literature on platelet concentrates and selecting the appropriate product for specific clinical applications.

First-generation platelet concentrates, typified by platelet-rich plasma (PRP), are prepared by drawing venous blood into anticoagulant-containing tubes, followed by a two-step centrifugation process that separates the blood into erythrocyte, buffy coat, and platelet-poor plasma fractions. The platelet-rich fraction is then activated with bovine thrombin and calcium chloride, inducing fibrin polymerization and platelet degranulation that releases growth factors in a rapid burst. PRP is a liquid formulation that lacks a robust fibrin scaffold and requires the addition of exogenous activators, introducing potential immunogenicity concerns related to bovine thrombin. PRP preparations vary widely in platelet concentration, leukocyte content, and growth factor yield due to the diversity of preparation protocols, complicating the interpretation of clinical studies.

Platelet-rich fibrin, the second-generation platelet concentrate introduced by Choukroun, eliminates anticoagulants and exogenous activators. Venous blood is drawn directly into glass or glass-coated plastic tubes without additives and immediately centrifuged. Contact activation of the coagulation cascade by the tube surface initiates physiological thrombin generation and fibrinogen polymerization, producing a dense fibrin clot that entraps platelets and leukocytes within its meshwork. The resulting PRF clot is a solid biomaterial that can be compressed into a membrane, cut into fragments, or used as a whole clot. The physiological polymerization process yields a tetramolecular fibrin structure with equilateral junctions, similar to natural blood clots, which provides superior mechanical strength and growth factor retention compared to the bimolecular junctions formed in PRP.

Variations in centrifugation protocol have produced distinct PRF formulations with different cellular and growth factor profiles. The original Leukocyte- and Platelet-Rich Fibrin (L-PRF), prepared with a centrifugation speed of approximately 2700 rpm (approximately 400 g) for 12 minutes, yields a clot with high leukocyte content concentrated in the distal portion of the fibrin matrix. The presence of leukocytes in L-PRF contributes to antimicrobial activity through phagocytosis and cytokine release, as well as to the regulation of the inflammatory phase of wound healing through the secretion of pro- and anti-inflammatory mediators.

Advanced Platelet-Rich Fibrin (A-PRF), introduced in 2014, employs a lower centrifugation speed of approximately 1500 rpm (approximately 200 g) for 14 minutes. The reduced g-force yields a fibrin matrix with a looser, more porous architecture and a more uniform distribution of platelets and leukocytes throughout the clot. In vitro studies demonstrate that A-PRF releases significantly higher concentrations of growth factors, including transforming growth factor-beta 1 (TGF-beta1), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF), over a 10-day period compared to L-PRF. The enhanced growth factor release profile of A-PRF is attributed to the more physiologic centrifugation conditions that minimize cellular damage and preserve platelet integrity.

Injectable Platelet-Rich Fibrin (i-PRF), described by Mourao et al. in 2015, is prepared using even lower centrifugation speeds (approximately 700 rpm, 60 g) for 3 minutes, producing a liquid formulation that can be injected or combined with bone graft materials to create a "sticky bone" composite. i-PRF retains the autologous nature and biological activity of PRF while offering the handling properties of a liquid, expanding its application to scenarios where a solid membrane is impractical. The liquid i-PRF polymerizes into a fibrin clot within approximately 10-15 minutes after collection, providing a window for injection or mixing with particulate grafts before solidification.

Biological Mechanisms of Action

The regenerative potential of PRF derives from the synergistic interaction of its three principal components: the fibrin matrix scaffold, platelets and their growth factor payload, and leukocytes and their immunomodulatory functions. Each component contributes to tissue regeneration through distinct but complementary mechanisms.

The fibrin matrix provides the architectural foundation for wound healing. The three-dimensional fibrin network serves as a scaffold for the migration, adhesion, and proliferation of mesenchymal stem cells, fibroblasts, osteoblasts, and endothelial cells. The tetramolecular fibrin structure characteristic of PRF, with its equilateral junction geometry, creates a more porous, elastic, and hydrophilic matrix than the bimolecular structure of PRP fibrin. This architecture facilitates cellular infiltration from the wound margins and the diffusion of nutrients and oxygen throughout the scaffold. Fibrin also binds fibronectin and vitronectin, extracellular matrix glycoproteins that mediate cell adhesion through integrin receptors, further enhancing the scaffold's cell-supportive properties.

Growth factor release from PRF follows a sustained-release profile that distinguishes it from the rapid burst release characteristic of PRP. Platelets within the fibrin matrix are activated physiologically during clot formation, degranulating to release their alpha-granule contents. However, a substantial fraction of growth factors remains bound within the fibrin matrix through specific molecular interactions, including the high-affinity binding of TGF-beta superfamily members to fibrinogen and fibrin. This binding creates a reservoir from which growth factors are progressively released through a combination of diffusion and enzymatic cleavage of the fibrin matrix by plasmin during the physiological process of fibrinolysis. In vitro studies demonstrate that PRF releases growth factors continuously for at least 7-14 days, with peak release occurring during the first 24-48 hours and sustained lower-level release throughout the study period.

The principal growth factors released by PRF and their biological functions have been extensively characterized. Platelet-derived growth factor (PDGF), a potent mitogen and chemoattractant, stimulates the proliferation and migration of mesenchymal stem cells and fibroblasts, promoting cellular repopulation of the wound site. Transforming growth factor-beta (TGF-beta), released in its latent form and activated in the acidic wound environment, stimulates extracellular matrix synthesis, including collagen type I production by fibroblasts, and regulates the differentiation of mesenchymal stem cells toward fibroblastic and osteoblastic lineages. Vascular endothelial growth factor (VEGF) promotes angiogenesis by stimulating endothelial cell proliferation, migration, and tube formation, supporting the revascularization of grafts and wound sites. Insulin-like growth factor (IGF) enhances the differentiation and matrix synthesis activities of osteoblasts, contributing to bone formation. Epidermal growth factor (EGF) stimulates epithelial cell proliferation and migration, promoting wound closure by epithelialization.

Leukocytes within PRF, predominantly neutrophils and monocytes concentrated in the distal portion of the clot closest to the buffy coat interface, contribute immunomodulatory and antimicrobial functions. Leukocytes secrete pro-inflammatory cytokines, including interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), which initiate the inflammatory phase of wound healing and recruit additional immune cells to the site. Concurrently, leukocytes release anti-inflammatory cytokines, including interleukin-4 (IL-4) and interleukin-10 (IL-10), that limit the intensity and duration of the inflammatory response, preventing excessive tissue damage. The phagocytic activity of neutrophils and monocytes provides antimicrobial defense against contaminating bacteria, reducing the risk of surgical site infection. The presence of leukocytes in PRF has been demonstrated to reduce bacterial colony-forming units in vitro, though the clinical significance of this antimicrobial activity in reducing post-operative infection rates remains to be established in prospective clinical trials.

Preparation Protocol and Technical Considerations

The preparation of PRF follows a standardized protocol that, when executed correctly, produces a consistent biomaterial with predictable biological properties. Attention to detail at each step of the protocol, from venipuncture to membrane compression, influences the quality and composition of the final product.

Venipuncture is performed using a butterfly needle or straight needle to collect approximately 10 mL of venous blood per tube directly into sterile glass or glass-coated plastic tubes without additives. The volume of blood collected should fill the tube to the manufacturer's indicated level to achieve the appropriate blood-to-surface-area ratio for contact activation. Tubes with silica or glass interior surfaces provide the optimal surface for contact activation of factor XII (Hageman factor), which initiates the intrinsic coagulation cascade. The use of plastic tubes without surface coating may result in incomplete coagulation and poor-quality fibrin clots.

Centrifugation must begin immediately after blood collection, with a recommended maximum delay of 60-120 seconds to prevent premature coagulation outside the centrifuge. The centrifuge should be balanced with tubes of equal weight, and the centrifugation protocol appropriate for the desired PRF formulation should be selected: approximately 2700 rpm (400 g) for 12 minutes for L-PRF, approximately 1500 rpm (200 g) for 14 minutes for A-PRF, or approximately 700 rpm (60 g) for 3 minutes for i-PRF. RCF (relative centrifugal force, measured in g) rather than RPM (revolutions per minute) should be used to specify centrifugation conditions, as RPM-to-RCF conversion depends on the rotor radius of the specific centrifuge. Centrifuges designed specifically for PRF preparation, including the IntraSpin (Intra-Lock) and Duo Quattro (Process for PRF), incorporate preset protocols that simplify the preparation process.

Following centrifugation, the blood separates into three distinct layers: a lower erythrocyte layer, a middle PRF clot layer, and an upper acellular plasma layer (platelet-poor plasma, PPP). The PRF clot is removed from the tube using sterile forceps and separated from the erythrocyte layer by cutting just below the buffy coat interface using sterile scissors. The fibrin clot is then placed in a PRF box or between sterile gauze and compressed to form a membrane. The compression pressure and duration influence the membrane thickness, porosity, and cellular distribution. Gentle compression over 1-2 minutes produces a membrane of approximately 1 mm thickness with preserved cellular viability, while aggressive compression can damage cells and expel growth factor-rich exudate from the matrix.

The PRF membrane should be used immediately after preparation for optimal biological activity. Growth factor release begins at the moment of clot formation, and viability of entrapped cells declines over time ex vivo. If a delay between preparation and clinical use is unavoidable, the PRF membrane can be stored briefly in a sterile, humidified container, though periods exceeding 20-30 minutes result in measurable degradation of biological activity. The manipulation of PRF should be performed on a sterile field with aseptic technique, as the fibrin matrix provides a nutrient-rich environment conducive to bacterial growth if contaminated.

Clinical Applications in Dentistry and Oral Surgery

The clinical applications of PRF span virtually all surgical disciplines within dentistry, with a substantial and growing evidence base supporting its use. The following sections review the principal clinical indications and the evidence for PRF efficacy in each application.

Socket preservation following tooth extraction is one of the most extensively studied applications of PRF. The placement of PRF into extraction sockets is intended to promote physiological healing, reduce alveolar ridge dimensional changes, and prepare the site for future implant placement. Systematic reviews and meta-analyses of randomized controlled trials comparing PRF with natural healing or other socket preservation techniques report that PRF significantly reduces horizontal and vertical ridge resorption, though the magnitude of the effect is modest. A 2022 meta-analysis by Canellas et al. reported a weighted mean reduction in horizontal ridge loss of 1.02 mm and vertical ridge loss of 0.67 mm favoring PRF over natural healing. PRF may be placed alone as the sole socket filling material or in combination with particulate bone graft materials to create a composite graft that combines the osteoconductive scaffold of the bone graft with the biological activity of PRF.

Guided bone regeneration (GBR) procedures, where PRF membranes are used either as barrier membranes alone or in combination with particulate grafts, represent another major clinical application. PRF membranes placed over particulate bone grafts serve as a biological barrier that excludes soft tissue ingrowth while supporting angiogenesis and osteoprogenitor cell migration into the graft. Compared to collagen barrier membranes, PRF offers the advantages of being completely autologous, resorbing through physiological fibrinolysis without foreign body reaction, and releasing growth factors that actively promote healing rather than serving as a passive barrier. A randomized controlled trial by Miron et al. (2021) demonstrated comparable bone regeneration with PRF membranes versus collagen membranes in lateral ridge augmentation when combined with a 50/50 mixture of autogenous bone and xenograft particulate, with significantly reduced post-operative pain and swelling in the PRF group.

Sinus floor elevation, both lateral window and transcrestal approaches, benefits from PRF as a sole grafting material or as an adjunct to particulate grafts. The angiogenic properties of PRF are particularly relevant in the sinus environment, where the maxillary sinus membrane provides the primary blood supply to the graft. A systematic review by Ali et al. (2020) reported that PRF alone as a sinus grafting material results in mean bone gain of 7-10 mm, with histomorphometric analysis demonstrating 25-35% new bone formation, values comparable to those achieved with particulate bone grafts. The use of PRF as a sole grafting material for sinus augmentation avoids donor site morbidity associated with autogenous bone harvesting and eliminates the cost and potential immunogenicity of xenograft materials. Furthermore, PRF membranes can be used to repair Schneiderian membrane perforations, with case series reporting successful repair rates exceeding 90%.

Periodontal regeneration, including the treatment of intrabony defects and furcation involvements, has been investigated as an application for PRF. Systematic reviews comparing open flap debridement plus PRF with open flap debridement alone for intrabony defects report statistically significant improvements in clinical attachment level gain (weighted mean difference approximately 1.1 mm) and probing depth reduction (weighted mean difference approximately 1.3 mm) favoring PRF. However, the magnitude of improvement with PRF is generally less than that achieved with enamel matrix derivative (EMD) or guided tissue regeneration (GTR) using barrier membranes, and PRF is considered a useful adjunct rather than a replacement for established periodontal regenerative techniques.

Gingival recession treatment with PRF membranes as an alternative or adjunct to connective tissue grafts has been evaluated in multiple randomized controlled trials. Meta-analyses report that coronally advanced flap (CAF) combined with PRF achieves mean root coverage of 75-85%, compared to 85-95% for CAF combined with connective tissue graft (CTG). The difference in complete root coverage rate is more pronounced, with CTG achieving complete coverage in 50-70% of defects compared to 30-50% for PRF. The principal advantage of PRF over CTG is the elimination of palatal donor site morbidity, making it an attractive option for patients who prioritize avoidance of a second surgical site over achieving optimal root coverage. PRF may also be indicated in patients with inadequate palatal tissue thickness for CTG harvesting.

Implant dentistry applications of PRF include implant site preparation, immediate implant placement, management of peri-implant bone defects, and treatment of peri-implantitis. During implant osteotomy preparation, the placement of PRF membranes or liquid i-PRF into the osteotomy before implant insertion is hypothesized to accelerate osseointegration by providing a concentrated source of growth factors at the bone-implant interface. In vitro and animal studies support this concept, demonstrating enhanced osteoblast differentiation and increased bone-to-implant contact with PRF-treated sites, though the clinical significance of these findings for implant success rates is not definitively established. For immediate implant placement in extraction sockets, PRF is used to fill the gap between the implant surface and the buccal bone wall, promoting bone fill of the jumping distance and preserving buccal bone thickness.

Endodontic applications of PRF, including regenerative endodontic procedures for immature teeth with necrotic pulps, represent a growing area of investigation. PRF serves as an autologous scaffold in regenerative endodontic protocols, replacing the traditional induced bleeding technique. The PRF membrane is placed over the blood clot at the level of the cementoenamel junction, providing a stable matrix for stem cell attachment and differentiation while releasing growth factors that promote the regeneration of pulp-like tissue and continued root development. Case series and preliminary clinical trials report continued root development and apical closure in 70-90% of PRF-treated immature permanent teeth, comparable to outcomes with induced bleeding alone. The use of PRF in regenerative endodontics avoids the need for additional traumatic instrumentation to induce bleeding in the apical region, potentially preserving the viability of the apical papilla stem cells.

Limitations and Contraindications

Despite its favorable biological profile and broad clinical utility, PRF has limitations and absolute and relative contraindications that should guide its selective application.

The primary limitation of PRF is the variability in its composition and biological activity. The growth factor content and cellular composition of PRF vary between patients and even between preparations from the same patient at different time points. Factors influencing PRF composition include the patient's age, systemic health status, medications (particularly antiplatelet agents and anticoagulants), hematocrit, and platelet count, as well as technical factors including centrifugation parameters, tube material, and membrane preparation technique. This inherent variability complicates the interpretation of clinical studies and the prediction of individual patient outcomes.

Absolute contraindications to PRF use include hematological disorders that prevent safe venipuncture or produce dysfunctional platelets, including severe thrombocytopenia, hemophilia, and platelet function disorders. Patients on anticoagulant or aggressive dual antiplatelet therapy present a relative contraindication due to the risk of persistent bleeding from the venipuncture site and the potential for impaired coagulation and suboptimal fibrin clot formation. Active systemic infection or sepsis is a contraindication, as the autologous transfer of blood products could theoretically disseminate infection.

The limited mechanical properties of PRF membranes constrain their application in load-bearing or space-maintaining scenarios. PRF membranes lack the compressive strength and volume stability of rigid barrier membranes and are rapidly resorbed through fibrinolysis, typically within 1-2 weeks. This rapid resorption limits the duration of the barrier function and growth factor release, and PRF membranes cannot be relied upon as the sole space-maintaining element in GBR procedures where prolonged membrane integrity is required. For such applications, the combination of PRF with a synthetic or xenograft barrier membrane that provides prolonged mechanical support is recommended.

The evidence base for PRF, while extensive, is characterized by significant heterogeneity in preparation protocols, outcome measures, and study populations. Many published studies lack standardized reporting of centrifugation parameters, PRF formulation, and patient characteristics, limiting the comparability and generalizability of findings. Furthermore, the majority of clinical trials have been conducted by a relatively small number of research groups, often with commercial interests in PRF preparation systems, raising the possibility of publication bias and sponsorship bias that may inflate reported effect sizes.

Future Directions

Research and development in PRF technology is advancing along several fronts, including protocol standardization, formulation modifications to enhance specific biological properties, and expansion of clinical indications through rigorous clinical trials.

Standardization of PRF preparation protocols is a priority for improving the quality and comparability of research and facilitating evidence-based clinical guidelines. The development of centrifuges with calibrated and validated protocols, such as those manufactured by Intra-Lock and Process for PRF, represents progress toward this goal. The International Academy of PRF (IAPRF) and other professional organizations have published consensus recommendations for PRF preparation that are being progressively adopted. Future research should report centrifugation conditions in terms of RCF (g-force) rather than RPM, specify tube material and dimensions, and document patient characteristics that may influence PRF composition.

Modified PRF formulations that incorporate therapeutic agents are an active area of investigation. Antibiotic-loaded PRF, prepared by adding metronidazole, amoxicillin, or clindamycin to the blood sample before centrifugation, has been evaluated for local antimicrobial delivery in infected sites. In vitro studies demonstrate sustained antibiotic release from PRF for up to 7 days, with concentrations exceeding the minimum inhibitory concentration (MIC) for common oral pathogens. Bisphosphonate-loaded PRF has been proposed for the management of medication-related osteonecrosis of the jaw (MRONJ), combining the wound-healing properties of PRF with the anti-resorptive activity of locally delivered bisphosphonate. While these modified formulations show promise in preclinical studies, clinical evidence for their efficacy is currently limited to case reports and small case series.

Lyophilized and freeze-dried PRF preparations, which can be stored at room temperature and rehydrated at the point of care, are being developed to address the limitation that fresh PRF must be used immediately after preparation. Lyophilized PRF retains its fibrin architecture and a fraction of its growth factor content following rehydration, though the biological activity is reduced compared to fresh PRF. Storable PRF formulations could extend the reach of PRF therapy to settings where on-site centrifugation is impractical, including mobile dental clinics and humanitarian missions.

Combination therapies that pair PRF with stem cells, growth factors, or biomaterials represent an emerging frontier. PRF combined with bone marrow aspirate concentrate (BMAC) or adipose-derived stem cells creates a composite graft with both scaffold and cellular components for enhanced regenerative capacity. The combination of PRF with recombinant human bone morphogenetic protein-2 (rhBMP-2) is being investigated for large bone defect reconstruction, where PRF provides a controlled-release delivery system for the osteoinductive growth factor. Tissue engineering applications, where PRF serves as a bioink for three-dimensional bioprinting of tissue constructs, represent a speculative but potentially transformative future direction.

Conclusion

Platelet-rich fibrin has established itself as a versatile and biologically active autologous biomaterial with broad applications across dental surgery. The simplicity of its preparation, favorable safety profile, and sustained release of growth factors from a biomimetic fibrin scaffold distinguish PRF from first-generation platelet concentrates and synthetic biomaterials. The evidence base, while heterogeneous, supports the clinical utility of PRF for socket preservation, guided bone regeneration, sinus augmentation, periodontal regeneration, and gingival recession treatment, with emerging applications in implant dentistry and regenerative endodontics.

The selection of PRF as an adjunct to surgical procedures should be guided by an understanding of its biological mechanisms, limitations, and the specific evidence for its efficacy in the intended application. PRF is not a universal substitute for established techniques and materials but rather a complementary tool that enhances healing through the delivery of autologous growth factors and provision of a fibrin scaffold. As protocol standardization improves and high-quality clinical trials expand the evidence base, the role of PRF in evidence-based surgical practice will continue to evolve.